Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported ...

TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps a Hold rating on the shares. The ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Citi analyst Patrick Donnelly lowered the firm’s price target on 10x Genomics (TXG) to $20 from $23 and keeps a Buy rating on the shares ...

Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...